- Conditions
- Achondroplasia
- Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 0 Years to 32 Months
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 42
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Transitional Cell Carcinoma, Platinum-Resistant Urothelial Carcinoma, Bladder Urothelial Carcinoma, FGFR Mutation, FGFR2 Gene Mutation, FGFR3 Gene Mutation, FGFR2 Amplification, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Carcinoma, Refractory Bladder Urothelial Carcinoma
- Interventions
- Balversa
- Drug
- Lead sponsor
- xCures
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Hypochondroplasia
- Interventions
- Not listed
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 30 Months to 16 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
- Interventions
- Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 677 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more
- Conditions
- Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions
- Interventions
- TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose TBD
- Drug
- Lead sponsor
- Tyra Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 35
- States / cities
- Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 30 more
- Conditions
- Achondroplasia
- Interventions
- Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more
- Conditions
- Advanced Cancer, Metastatic Cancer
- Interventions
- LY3076226
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Charleston, South Carolina • San Antonio, Texas
- Conditions
- Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy, Immune-Mediated Neuropathy
- Interventions
- Panzyga IVIG, Placebo
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Glenview, Illinois
- Conditions
- Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
- Interventions
- KIN-3248
- Drug
- Lead sponsor
- Kinnate Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • La Jolla, California • Jacksonville, Florida + 9 more
- Conditions
- Developmental Bone Disease, Dwarfism, Skeletal Dysplasias
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Achondroplasia
- Interventions
- Infigratinib
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Interventions
- B-701, Pembrolizumab
- Drug
- Lead sponsor
- Rainier Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Greenbrae, California • Fort Wayne, Indiana • Louisville, Kentucky + 5 more
- Conditions
- Hypochondroplasia
- Interventions
- Infigratinib
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Achondroplasia
- Interventions
- Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Oakland, California • Wilmington, Delaware • Baltimore, Maryland + 2 more
- Conditions
- Solid Tumor
- Interventions
- Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D)
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more
- Conditions
- Craniosynostosis, Muenke Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2020
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Achondroplasia
- Interventions
- Not listed
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 30 Months to 17 Years
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more
- Conditions
- Urothelial Cancer
- Interventions
- TKI258
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Chicago, Illinois + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- PHA-739358
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Chicago, Illinois
- Conditions
- Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
- Interventions
- Intravenous immunoglobulin, 0.9% Sodium Chloride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
- Interventions
- CGT4859
- Drug
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more
- Conditions
- Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
- Interventions
- Erdafitinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Solid Tumor
- Interventions
- BHV-1530, Cemiplimab
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 17
- States / cities
- Newport Beach, California • Denver, Colorado • Lake Mary, Florida + 14 more
- Conditions
- Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma
- Interventions
- TYRA-430
- Drug
- Lead sponsor
- Tyra Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 6 more